A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors.
Janku F, Choong GM, Opyrchal M, Dowlati A, Hierro C, Rodon J, Wicki A, Forster MD, Blagden SP, Yin J, Reid JM, Muller H, Cmiljanovic N, Cmiljanovic V, Adjei AA.
Janku F, et al. Among authors: wicki a.
Cancers (Basel). 2024 Mar 13;16(6):1137. doi: 10.3390/cancers16061137.
Cancers (Basel). 2024.
PMID: 38539472
Free PMC article.